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The first cell growth factor, nerve growth factor (NGF), was discovered by Rita Levi-Montalcini (RLM) in the early 1950’s in 
Washington University in Saint Louis, Missouri, USA. Originally identified as neurite outgrowth-stimulating factor, later stud-
ies revealed that non-neuronal cells, including immune cells, endothelial cells, cardiomyocytes, pancreatic beta cells, prostate 
epithelial cells and adipose tissue cells, are also targets for and/or sources of NGF. Nerve growth factor is well recognized at 
present to mediate multiple biological phenomena, ranging from the neurotrophic through immunotrophic and epitheliotrophic 
to metabotrophic effects. Consequently, NGF and other members of the neurotrophin family are implicated in the pathogenesis 
of a large spectrum of neuronal and non-neuronal diseases, ranging from Alzheimer’s and other neurodegenerative diseases 
to atherosclerosis and other cardiometabolic diseases. Recent studies demonstrated the therapeutic potentials of NGF in these 
diseases including ocular and cutaneous diseases. Whereas NGF TrkA receptor antagonists emerged as novel drugs for pain, 
prostate and breast cancer, and urinary bladder syndromes. Here we briefly describe (i) the “unpredictable” ideogenesis of the 
discovery of NGF, and (ii) our scientific and human experience working in RML’s laboratory for 15 years (GNC) and over 40 
years (LA). Biomed Rev 2012; 23: 1-7.
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INTRODUCTION
Rita Levi-Montalcini (RLM) was born April 22, 1909 in Turin, 
Italy, where received her medical degree from the University 
of Turin in 1936. The same year she entered the Institute of 
Anatomy as postgraduate student of Professor Giuseppe Levi, 
a well-known neuroanatomist and tutor of two other future 
Nobel Prize winners in Physiology or Medicine, Salvadore 
Luria (in 1969) and Renato Dulbecco (in 1975).  During her 
early postgraduate years, she studied the relationship between 
the developing nervous system and its peripheral targets and 
observed that many sensory neurons died during normal devel-
opment, and that the limb bud extirpation caused an increase 
in the number of nerve cell death. The results of these studies 
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lead her to the hypothesis that the failure of neurons to thrive in 
the absence of peripheral target was because of a degenerative 
process rather than a failure of differentiation, as had previ-
ously been hypothesized by Victor Hamburger, a well-known 
neuroembryologist working at the Department of Zoology, 
Washington University in St. Louis, MO.  In 1946, Hamburger 
invited Levi-Montalcini to join his group to reinvestigate their 
scientific disagreements. In their initial published work Levi-
Montalcini and Hamburger (1951) prospected the hypothesis 
that the nerve-target interactions are reciprocally competitive 
in the sense that developing neurons depend on feedback (ret-
rograde) signals from the peripheral tissues that are required for 
neuronal survival. These seminal observations and hypothesis 
pawed the way to the discovered of programmed cell death (in 
the today’s context, the apoptosis), and later the discovery of 
nerve growth factor (NGF).  
THE ROAD OF DISCOVERY 
At the end of the nineteenth century, it was envisaged by San-
tiago Ramon y Cajal but has  not been proven that life at the 
neuronal level requires trophic support. The proof was obtained 
by work initiated by  Rita Levi-Montalcini in 1949. Then she 
first saw the results of Elmer Bueker, a former student of Ham-
burger, showing the effect of transplanting mouse sarcoma 180 
into a chick embryo. Bueker observed that upon transplanta-
tion, the tumor stimulated the growth of fibers from neurons 
of the sensory ganglia into the tumor, just as they would have 
done into transplanted limbs and even more vigorously. He 
interpreted this result writing that the tumor transplantation 
effect was greater because the tumor provided a larger target 
area for the cells to expand than a limb would have. This 
interpretation did not convince Levi-Montalcini and follow-
ing the suggestion of Hamburger then decided to repeat this 
experiment. She found the same result, but reached a different 
interpretation, hypothesizing that the transplanted tumor tissue 
induced hyperinnervation of internal chick organs by releasing 
a diffusible agent that stimulated the growth and differentiation 
of developing nerve cells. Using in vitro analysis, she studied 
the effect of this extract on isolated sensory and sympathetic 
nerve cells and clearly demonstrated the direct stimulating ac-
tion of the tumor extract on nerve growth and named initially 
this yet unknown molecule nerve growth-stimulating factor, 
later termed NGF (Levi-Montalcini and Hamburger,1951; 
Levi-Montalcini 1952; Levi-Montalcini and Booker 1960). 
In attempt to purify the tumor-derived factor, Levi-Montal-
cini and Stanly Cohen used snake venom as a rich source of 
phosphodiesterase, a nucleic acid-destroying enzyme, for the 
separation of nucleic acids and protein fractions in the tumor 
material. To their great surprise, the tumor fraction containing 
the snake venom was several thousand-fold more potent than 
control tumor homogenate in promoting nerve growth, both 
in vitro and in vivo. Further on the road of discovery, Levi-
Montalcini and Cohen examined the mammalian homologue 
of the snake venom, the salivary gland, and found that the male 
mouse submandibular glands were an even richer source of 
the same nerve growth-stimulating activity found in both the 
tumor and the snake venom. Thus male mouse submandibular 
glands appeared to be a new and possibly largest source of 
NGF providing the possibility to isolate and purified consist-
ent amount of this intriguing biomolecule. In effect, such an 
unpredictable experimental cascade (from tumor via snake 
venom to salivary glands) resulted in the discovery of NGF in 
1951, a heuristic phenomenon marked by a rare combination 
of scientific reasoning, intuition, and chance.
THE NGF AND ITS RECEPTORS 
Since its discovery, NGF becomes one of the best-char-
acterized members of the protein family of neurotrophic 
factors designated neurotrophins, including NGF, BDNF, 
NT-3/4, NT-5, NT-6, and NT-7) (Aloe and Calzá, 2004). The 
biological action of NGF is mediated by (i) the high-affinity 
receptor TrkA (tropomyosin-related kinase receptor A; also 
known as tyrosine kinase receptor), and (ii) the low-affinity 
receptor termed p75 (pan)neurotrophin receptor (p75NTR). 
In most cases, TrkA expression exerts protective actions on 
diseases involving degeneration of NGF target cells. In these 
diseases, the balance of TrkA and p75NTR signaling pathways 
is altered through different mechanisms including co-receptor 
modulation. TrkA receptor agonists may provide alternatives 
in therapy of neurodegenerative and psychiatric diseases (see 
below). Of note, the NGF precursor proNGF induces apoptosis 
through p75NTR (Fahnestock et al, 2004).
     
NGF AND NON-NEURONAL CELLS 
As often occurs, the framework of an initial conception of the 
physiological role of a newly discovered molecule extends 
in the light of emerging findings. This was also the case with 
NGF.  During some 25 years after its discovery, for example, 
there have been few reasons given to indicate that NGF acts 
on non-neuronal cells. Thus, in 1975, Luigi Aloe and Levi-
Montalcini have made a remarkable experiment demonstrating 
that treatment of newborn rats with NGF caused a systemic 
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increase in the number of mast cells. This seminal finding, 
published in Brain Research in 1977, has  triggered the study 
on neuroimmune connections, leading to  today’s accumulation 
of  compelling evidence  that NGF is wider than the neuron 
(paraphrasing Emily Dickinson’s The brain is wider than the 
sky). That is, in addition to its neurotrophic function, this tal-
ented molecule influences the survival and activity of a large 
number of “unpredictable”, non-neuronal cells such as immune 
cells, fibroblasts, epithelial cells, pancreatic beta cells, adipose 
tissue cells, and cardiomyocytes (Aloe et al, 1994; Aloe and 
Chaldakov, 1999; Aloe and Calzá, 2004, Marinova et al, 2004; 
Larrieta et al, 2006; Sornelli et al, 2009; Meloni et al, 2010; 
Lam et al, 2012).  Such non-neuronal actions of NGF, also 
of other neurotrophic factors subsequently discovered, open 
novel avenues in the study of neurobiology, namely, neuroim-
munology (Aloe and Levi-Montalcini, 1977) and, recently, 
neuroadipology (Chaldakov et al, 2010). Thus, we witness, 
appreciate, and, hopefully, contribute to an exciting time in 
the field of integrative physiology (systems biology) of NGF, 
we also termed “NGF-ome”. Pioneering studies published by 
Enrico Alleva in collaboration with Levi-Montalcini and Aloe 
revealed a pivotal role of NGF in aggressive and anxiety-like 
behaviors  (Alleva et al, 1993). 
Altogether, “the submerged areas of the NGF iceberg loom 
very large”, Rita Levi-Montalcini (1987) stated in her Nobel 
prize lecture reviewing 35 years of research on NGF.  
THE THERAPEUTIC NGF    
The treatment of diabetic polyneuropathy was one of earliest 
indication sought for clinical trial of NGF. The first results 
of these studies are at the moment controversial. Subsequent 
studies investigating the effect of NGF administration in ro-
dent forebrain cholinergic neurons and behavior and memory 
performances lead to the hypothesis that NGF may be useful to 
protect these neurons that are known to degenerate in brain of 
subjects affected by Alzheimer’s disease. While the therapeu-
tic potential of NGF in the treatment of neurotrophic corneal 
ulcers, skin ulcers, glaucoma and Alzheimer’s disease (Aloe 
et al, 2004, 2012) seems clearly demonstrated, the use of NGF 
as drug is to some extend limited for its not fully established 
pharmacokinetics and the high cost associated with the produc-
tion of human recombinant NGF. These obstacles have driven 
the scientific community also toward the identification of small 
molecules (NGF mimetics) with drug-like properties. These 
molecules may (i) directly bind to NGF receptors causing their 
activation, (ii) enhance the release of endogenous NGF, and/
or (iii) influence intracellular signaling pathways.
Several therapeutic strategies to delivery NGF in animal 
models and in human diseases have been explored and clinical 
steps have been attempted, while others are currently in pro-
gress to evaluate whether NGF and/or TrkA receptor agonists 
can prevent or protect against cell degeneration in the nervous 
system, visual system, cutaneous and myocardial  tissue (Yuen 
et al, 1996; Apfel et al, 1998; Lambiase et al, 1998; Bernabei 
et al, 1999; Landi et al, 2003; Chiretti et al, 2002; Lambiase et 
al, 2009a; Lambiase et al, 2009b; Meloni et al, 2010; Lam et 
al, 2012; Aloe et al, 2012). And most likely to exert therapeutic 
effects on cardiometabolic diseases such as atherosclerosis, 
obesity, type 2 diabetes and metabolic syndrome (Chaldakov 
et al, 2004, 2009; Chaldakov, 2011). Contrary, TrkA receptor 
antagonists emerged as novel drugs for prostate (Weeraratna 
et al, 2000) and breast (Romon et al, 2010) cancer, bladder 
syndromes (Ochodnický et al, 2011) and various pain condi-
tions (Mantyh et al, 2011). Intriguingly, NGF may contribute 
to romantic love (Emanuele et al, 2006; Emanuele, 2011).
The experimental approach also includes recombinant hu-
man neurotrophin application, direct gene transfer using (non-)
viral vectors, the implantation of ex vivo genetically engineered 
cells secreting neurotrophic factors, and the grafting of neural 
stem progenitor cells. Every second years, experts in the field 
of NGF and other neurotrophic factors organize an interna-
tional scientific meeting in different countries.
THE QUEEN OF NEUROSCINECE 
Rita Levi-Montalcini has published more than 200 scien-
tific articles which contributed in depth to the excellence of 
modern neuroscience. She had an unlimited interest both in 
scientific and human activities and is a member of numerous 
national and international scientific academies. In 1968 she 
was elected member of the National Academy of Science of 
USA. In 1972 – member of the American Association of Art 
and Science. In 1986 she was awarded Albet Lasker Award 
for Basic Medical Research, a precursor of Nobel prize she 
received in 1986 (Photograph 1).
In 1974 she was the first woman elected member of the 
Pontifical Academy of Sciences of the Vatican. Then Dr Tom 
Woolsey, the George H. and Ethel R. Bishop Scholar in Neuro-
science at the School of Medicine, said: “When Levi-Montalcini 
was appointed to the Pontifical Academy by Pope Paul VI, the 
protocol required her to kneel and kiss the Pope’s hand. Rita 
said: “I simply stood and shook the Pope’s hand.” In her inde-
pendence and determination, she was a model for all scientists”.
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In 2001 RLM was nominated Senator of the Italian Par-
liament. She wrote several books: The Praise of Imperfec-
tion, her autobiography (dedicated to her 100th Anniversary, 
GNC wrote In Praise of Perfection published in Bulgarian 
journal InSpiro volume 6, 2009); The Saga of Nerve Growth 
Factor, an anthology of key scientific papers on this subject 
by herself and others (Levi-Montalcini, 1997); Ninety Years 
in the Galaxy of the Mind, which described her continu-
ing research of the brain and presented a system of ethics 
of future generations; Cantico di una Vita (Song of Life), a 
series of about 200 letters written to her mother during the 
years she made her key discoveries (Levi-Montalcini, 1996; 
Levi-Montalcini, 1998; Levi-Montalcini, 2000).
THE COLLABORATORS 
During her long scientific life, numerous young and senior 
scientists worked in RLM’s laboratory. Many of them collabo-
rated with her with long and short periods but contributed very 
little to the NGF studies. Others like Enrico Alleva in Italy and 
Ralph Bradshaw in USA  gave novel contributions to the to 
the NGF studies. However, reading The Saga of Nerve Growth 
Factor and her numerous scientific publications, one can 
come to the conclusion that she had three major collaborators, 
Stanley Cohen (1953-1959), Pietro Angeletti (1959-1970), and 
Luigi Aloe (1968-2010). 
Stanley Cohen, a biochemist contributed to study the early 
biochemical properties of the tumor extract and was the first 
Photograph 1. The Nobel Prize Award Ceremony, 10 December 1986, Stockholm: Rita Levi-Montalcini receives 
the Nobel Prize form King Carl Gustaf XVI of Sweden.
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to purify the NGF from the snake venom and from the mouse 
salivary gland and to produce the anti-NGF antibodies. He 
shared with Levi-Montalcini the Nobel Price in 1986 for the 
discovered the epidermal growth factor. 
Pietro Angeletti, a pathologist with an excellent preparation 
in biochemistry, made a substantial contribution to the study of 
NGF purification and to analysis of the spectrum of action of 
NGF in the peripheral nervous system and of the mechanism 
of immunosympathecotomy  during early postnatal life. 
Luigi Aloe (LA) first met Rita Levi-Montalcini in April 
1967, at the Instituto Superiore of Sanità in Rome for an inter-
view, while she was observing under the microscope the effect 
of anti-NGF antibody administration on the superior cervical 
ganglia of mice. The interview lasted about 20 minutes and two 
weeks later she called him asking if he would accept to work 
in her Laboratory in the Department of Zoology of the Wash-
ington University in St. Louis, Missouri, USA, for 6 months 
to take care of raising cockroaches for her studies on the insect 
nervous system.  Luigi Aloe accepted her proposal, thereafter 
the 6 months became 12, then two years and, consequently, 
over 40 years. He contributed to identification of new NGF 
target cells within and outside the nervous system, particularly 
in immune cells, endocrine system and adipose tissue (as 
described above in NGF AND NON-NEURONAL CELLS). 
In the last few years, LA, in collaboration with clinicians, 
discovered that NGF is an important therapeutic molecule 
for healing the corneal, pressure and diabetic ulcers, as well 
as degenerating retinal cells in glaucoma and maculopathy. 
This latter observation has proved to be useful also for Levi-
Montalcini herself who suffers of the latter ocular disorder. 
In 2002 LA organized the 7th International Meeting on 
“NGF and related molecules in
Health and Disease” in Modena, Italy (Chaldakov, 2002); 
in 2004 “Clinical Applications of NGF” Meeting in Rome, 
and another Rome meeting to celebrate the 100 years of Levi-
Montalcini, on 21 April 2009 (see Photograph 2).   
Photograph 2. Rita Levi-Montalcini and participants of the Rome-2009 meeting dedicated to her 100th birthday. 
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RESULTS OF A DREAM
During his student life at the Medical University, Varna, Bul-
garia, one of us (GNC) used to work four years (1962-1966) 
as research associated at the Department of Pharmacology. 
It was that period of time when he - for the first time – met 
in libro Rita Levi-Montalcini, reading her first NGF articles. 
Since then he has being infected by this talented molecule, 
and thought how to reach her Institute in Rome, Italy. Al-
though some colleagues told him that it is very much difficult 
pursuit, he continued to believe in his dream. On its road, in 
1997 he has applied for NATO Research Fellowship, which 
required acceptance letter by the host institution. Obviously, 
his dream asked Luigi Aloe about and he provided him with 
such a letter, and consequently awarded a fellowship allow-
ing him appeared in the Institute of Neurobiology, CNR, 
Rome, in June 1998. During this first four months there as 
well as almost each year further on, he was honored of meet-
ing in vivo many times Rita Levi-Montalcini. 
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